Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.69 |
| ▸ | MEN1 | O00255 | 4/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.60 |
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 5/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13701703 | 0.83 | SMN1; SMN2 (0.58) | RAB9AMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL2282705 | 0.83 | MAOA (0.48) | RAB9AMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL26336375 | 0.82 | MEN1 (0.71) | RAB9AMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL14712636 | 0.82 | MEN1 (0.76) | RAB9AMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL25633891 | 0.81 | LMNA (0.46) | RAB9AMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL13701740 | 0.81 | LMNA (0.58) | RAB9AMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL13543249 | 0.80 | MEN1 (0.62) | RAB9AMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL13702324 | 0.79 | KMT2A (0.81) | RAB9AMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL13701739 | 0.79 | LMNA (0.48) | RAB9AMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL21249304 | 0.79 | LMNA (0.58) | RAB9AKMT2AALDH1A1LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | FLECK ROMAN WOLFGANG | 2009-09-10 | — | — | US | disclosed |
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | FLECK ROMAN WOLFGANG | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | EPHX1, EPHX2, EPX | RAB9A 2708/4885MEN1 4409/4885KMT2A 3792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.